Lexicon Pharmaceuticals | LXRX - Interest Expense On Debt


Lexicon Pharmaceuticals reported $2.03M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Abbott USD 299M 231M Jun/2026
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
Akebia Therapeutics 349.66M 12.86M Jun/2026
Alnylam Pharmaceuticals USD 82.05M 12.76M Jun/2026
AstraZeneca USD 340M 144M Jun/2026
BioMarin Pharmaceutical USD 63.29M 48.34M Jun/2026
Coherus Biosciences USD 2.25M 76K Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Halozyme Therapeutics USD 5.59M 80K Jun/2026
Illumina USD 24M 2M Mar/2026
Insmed USD 18.84M 1.24M Jun/2026
Ironwood Pharmaceuticals USD 8.74M 506K Dec/2024
J&J USD 43M 25M Mar/2026
Lexicon Pharmaceuticals USD 2.03M 124K Dec/2025
MacroGenics USD 4.89M 1.55M Mar/2026
MannKind USD 14.82M 2.38M Jun/2026
Merck USD 525M 46M Jun/2026
Moderna USD 10.96B 527M Jun/2026
Novartis USD 462M 119M Jun/2026
PTC Therapeutics USD 3.25B 381.37M Jun/2026
Puma Biotechnology USD 3.37M 11K Jun/2024
Sarepta Therapeutics USD 21.51M 205K Jun/2026
Thermo Fisher Scientific USD 354M 11M Mar/2026
Ultragenyx Pharmaceutical USD 22M 1000K Jun/2026
United Therapeutics USD 2.9M 200K Jun/2026
Vanda Pharmaceuticals -1.37B 1.97B Dec/2025